Neural tube defects
from primary to quaternary prevention
Keywords:
neural tube, disease prevention, quaternary prevention, health promotionAbstract
There are four levels of health prevention: primary, secondary, tertiary and quaternary. The objective of this review was to draw a parallel between the line of obstetric care available in cases of neural tube defects and the prevention levels, highlighting the levels of evidence for the recommendations at each scale of prevention. Neural tube defects are congenital anomalies related to neuroaxis malformation that may affect the skull and/or the cervical, thoracic, lumbar and sacral spine, leading to secondary disruptions or deformations.
Downloads
References
Arouca ASS. O Dilema Preventivista. Contribuição para compreensão e crítica da medicina preventiva [tese]. Campinas: Faculdade de Ciências Médicas, Universidade Estadual de Campinas; 1975.
Torres CH. Ensino de Epidemiologia na Escola Médica: institucionalização da epidemiologia como disciplina na faculdade de medicina da Universidade Federal do Rio de Janeiro [dissertaçã o]. Rio de Janeiro: Escola Nacional de Saúde Pública da Fundação Oswaldo Cruz; 2002.
Leavell H, Clark E. Textbook of Preventive Medicine. 3ª ed. Nova York: McGraw-Hill; 1953.
Almeida LM. Da prevenção primordial à prevenção quaternária. Rev Port Saúde Pública. 2005;23(1):91-5.
Kuehlein T, Sahedoni D, Visentin G, Gérvas J, Jamoulle M. Prevenção quaternária, uma tarefa do clínico geral. Primary Care. 2010;1(18):1-13.
Alwan A. Noncommunicable diseases a major challenge for public health in the region. East Mediterr Health J. 1997;3(1):6-16. 7. Jekel JF, Elmore JG, Katz DL. Epidemiologia, bioestatística e medicina preventiva. Porto Alegre: Artmed; 1999.
Czeresnia D. Ações de promoção à saúde e prevenção de doenças: papel da ANS. Fórum de Saúde Suplementar [Internet]. 2003 [citado em xx mês. 201x]. 35 p. Disponível em: http://www.bvsde.paho.org/bvsacd/cd65/AcoesPromocaoSaude.pdf
Jamoulle M. Information et Informatisation en Médecine Générale. In: Troisiemes Journees de Reflexion sur L’informatique. Namur: Presses Universitaires de Namur; 1986, p.193-209.
Kleinman A. The Illness Narratives: Suffering, Healing and the Human Condition. Nova York: Basic Books; 1988.
Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 187: Neural tube defects. Obstet Gynecol. 2017;130:e279-90. https://doi.org/10.1097/AOG.0000000000002412
Wilson RD, SOGC Genetics Committee. Prenatal Screening, Diagnosis, and Pregnancy Management of Fetal Neural Tube Defects. J Obstet Gynaecol Can. 2014;36(10):927-39. https://doi.org/10.1016/S1701-2163(15)30444-8
Moretti ME, Bar-Oz B, Fried S, Koren G. Maternal hyperthermia and the risk for neural tube defects in offspring: systematic review and meta analysis. Epidemiology. 2005;16:216-9.
Wallingford JB, Niswander LA, Shaw GM, Finnell RH. The continuing challenge of understanding, preventing, and treating neural tube defects. Science. 2013;339:1222002. https://doi.org/10.1126/science.1222002
Zaganjor I, Sekkarie A, Tsang BL, Williams J, Razzaghi H, Mulinare J, et al. Describing the prevalence of neural tube defects worldwide: a systematic literature review. PLoS One. 2016;11:e0151586. https://doi.org/10.1371/journal.pone.0151586
De-Regil LM, Fernández-Gaxiola AC, Dowswell T, Peña-Rosas JP. Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev. 2010;10:CD007950. https://doi.org/10.1002/14651858.CD007950.pub2
Patanwala I, King MJ, Barrett DA, Rose J, Jackson R, Hudson M, et al. Folic acid handling by the human gut: implications for food fortification and supplementation. Am J Clin Nutr. 2014 Aug;100(2):593-9. https://doi.org/10.3945/ajcn.113.080507
Spiegelstein O, Mitchell LE, Merriweather MY, Wicker NJ, Zhang Q, Lammer EJ, et al. Embryonic development of folate binding protein-1 (Folbp1) knockout mice: effects of the chemical form, dose, and timing of maternal folate supplementation. Dev Dyn. 2004;231:221-31. https://doi.org/10.1002/dvdy.20107
Smithells RW, Sheppard S, Schorah CJ. Vitamin deficiencies and neural tube defects. Arch Dis Child. 1976;51:944-50. 20. Wierzbicki AS. Homocysteine and cardiovascular disease: a review of the evidence. Diab Vasc Dis Res. 2007;4:143-50. https://doi.org/10.3132/dvdr.2007.033
Casas JP, Bautista LE, Smeeth L, Sharma, P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet. 2005;365:224-32. https://doi.org/10.1016/S0140-6736(05)17742-3
Lamers Y, Prinz-Langenohl R, Moser R, Pietrzik K. Supplementation with [6S]-5-methyltetrahydrofolate or folic acid equally reduces plasma total homocysteine concentrations in healthy women. Am J Clin Nutr. 2004;79(3):473-8. https://doi.org/10.1093/ajcn/79.3.473
Denny KJ, Jeanes A, Fathe K, Finnell RH, Taylor SM, Woodruff TM. Neural tube defects, folate, and immune modulation. Birth Defects Res A Clin Mol Teratol. 2013 Sep;97(9):602-9. https://doi.org/10.1002/bdra.23177
Agência Nacional de Vigilância Sanitária. Resolução RDC nº 344, de 13 de dezembro de 2002 [Internet]. 2002 [citado em 15 maio 2018]. Disponível em: http://portal.anvisa.gov.br/documents/10181/2718376/RDC_344_2002_COMP.pdf/b4d87885-dcb9-4fe3-870d-db57921cf73f
Pacheco SS, Braga C, Souza AI, Figueroa JN. Rev Saúde Pública. Efeito da fortifi cação alimentar com ácido fólico na prevalência de defeitos do tubo neural. 2009;43(4):565-71.
Baldino CF. Prevalência de defeitos do tubo neural no estado de São Paulo antes e após a fortificação das farinhas com ácido fólico [dissertação]. São Paulo: Escola de Enfermagem, Universidade de São Paulo; 2011.
Federação Brasileira das Associações de Ginecologia e Obstetrícia. Guia Prático de Condutas – Recomendação sobre a suplementação periconcepcional de ácido fólico na prevenção de defeitos de fechamento do tubo neural. Rio de Janeiro: Febrasgo; 2012.
Obeid R, Holzgreve W, Pietrzik K. Is 5-methyltetrahydrofolate an alternative to folic acid for the prevention of neural tube defects? J Perinat Med. 2013;41(5):469-83. https://doi.org/10.1515/jpm-2012-0256
Bailey SW, Ayling JE. The pharmacokinetic advantage of 5-methyltetrahydrofolate for minimization of the risk for birth defects. 2018 [citado em xx mês. 201x]. Disponível em: https://www.nature.com/articles/s41598-018-22191-2 https://doi.org/10.1038/s41598-018-22191-2
Cuckle HS, Wald NJ, Cuckle PM. Prenatal screening and diagnosisof neural tube defects in England and Wales in 1985. Prenat Diagn. 1989;9:393-400.
Chaoui R, Benoit B, Mitkowska-Wozniak H, Heling KS, Nicolaides KH. Assessment of intracranial translucency (IT) in the detection of spina bifida at the 11–13-week scan. Ultrasound Obstet Gynecol. 2009;34:249-52. https://doi.org/10.1002/uog.7329
Bernard JP, Cuckle HS, Stirnemann JJ, Salomon LJ, Ville Y. Screening for fetal spina bifida by ultrasound examination in the first trimester of pregnancy using fetal biparietal diameter.Am J Obstet Gynecol. 2012 Oct;207(4):306. https://doi.org/10.1016/j.ajog.2012.05.014
Salomon LJ, Alfirevic Z, Bilardo CM, Chalouhi GE, Ghi T, Kagan KO, et al. ISUOG Practice Guidelines: performance of first-trimester fetal ultrasound scan. Ultrasound Obstet Gynecol. 2013;41:102-13.
Michejda M. Intrauterine treatment of spina bifida: primate model. Z Kinderchir. 1984;39(4):259-61. https://doi.org/10.1055/s-2008-1044221
Adzick NS, Thom EA, Spong CY, Brock JW 3rd, Burrows PK, Johnson MP, et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med. 2011 Mar 17;364(11):993-1004. https://doi.org/10.1056/NEJMoa1014379
Pedreira DA, Zanon N, Nishikuni K, Moreira de Sá RA, Acacio GL, Chmait RH, et al. Endoscopic surgery for the antenatal treatment of myelomeningocele: the CECAM trial. Am J Obstet Gynecol. 2016 Jan;214(1):111.e1-111.e11. https://doi.org/10.1016/j.ajog.2015.09.065
Wilson RD, Lemerand K, Johnson MP, Flake AW, Bebbington M, Hedrick HL, et al. Reproductive outcomes in subsequent pregnancies after a pregnancy complicated by open maternal-fetal surgery (1996-2007). Am J Obstet Gynecol. 2010 Sep;203(3):209.e1-6. https://doi.org/10.1016/j.ajog.2010.03.029
